Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null Mutation

High, K. A.2000. Gene therapy for disorders of hemostasis. In Hematology 2000: American Society of Hematology Education Program BookG. P. Schechter, Ed. pp. 252–265. Kay, 1999, Gene therapy for the hemophilias, Proc. Natl. Acad. Sci. USA., 96, 9973, 10.1073/pnas.96.18.9973 Connelly, 1996, Complete short-term correction of canine hemophilia A by in vivo gene therapy, Blood., 88, 3846, 10.1182/blood.V88.10.3846.bloodjournal88103846 Herzog, 1999, Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector, Nat. Med., 5, 56, 10.1038/4743 Snyder, 1999, Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors, Nat. Med., 5, 64, 10.1038/13518 Kay, 2000, Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector, Nat. Genet., 24, 257, 10.1038/73464 High, 1995, Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation, Adv. Exp. Med. Biol., 386, 79, 10.1007/978-1-4613-0331-2_6 Chao, 1999, Persistent expression of canine factor IX in hemophilia B canines, Gene Ther., 6, 1695, 10.1038/sj.gt.3301024 Gallo-Penn, 2001, Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs, Blood., 97, 107, 10.1182/blood.V97.1.107 Wang, 2000, Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver, Mol. Ther., 1, 154, 10.1006/mthe.2000.0031 Mauser, 1996, A deletion mutation causes hemophilia B in Lhasa Apso dogs, Blood., 88, 3451, 10.1182/blood.V88.9.3451.bloodjournal8893451 Arruda, 2001, Posttranslational modifications of recombinant myotube-synthesized human factor IX, Blood., 97, 130, 10.1182/blood.V97.1.130 Herzog, 1997, Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA., 94, 5804, 10.1073/pnas.94.11.5804 Herzog, 1999, Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy, Thromb. Haemost., 82, 540, 10.1055/s-0037-1615877 Evans, 1989, Canine hemophilia B resulting from a point mutation with unusual consequences, Proc. Natl. Acad. Sci. USA., 86, 10095, 10.1073/pnas.86.24.10095 Herzog, 2000, Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony, Thromb. Haemost., 84, 352, 10.1055/s-0037-1614021 Armstrong, 2000, Immune responses in hemophilia B mice expressing a speciesspecific transgene, Mol. Ther., 1, S29 Lin, 1997, A coagulation factor IX-deficient mouse model for human hemophilia B, Blood., 90, 3962, 10.1182/blood.V90.10.3962 Fields, 2000, Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX, Mol. Ther., 1, 225, 10.1006/mthe.2000.0032 Fields, 2001, Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9, Mol. Ther., 4, 201, 10.1006/mthe.2001.0441 Warrier, 1997, Factor IX inhibitors and anaphylaxis in hemophilia B, J. Ped. Hematol. Oncol., 19, 23, 10.1097/00043426-199701000-00003 Fields, 2001, Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice, Gene Ther., 8, 354, 10.1038/sj.gt.3301409 Nilsson, 1986, Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies, Proc. Natl. Acad. Sci. USA., 83, 9169, 10.1073/pnas.83.23.9169 Mayumi, 1996, Cyclophosphamide-induced immunological tolerance: an overview, Immunobiology., 195, 129, 10.1016/S0171-2985(96)80033-7 Matsushita, 1998, Adeno-associated virus vectors can be efficiently produced without helper virus, Gene Ther., 5, 938, 10.1038/sj.gt.3300680 Whitney, 1994, The molecular basis of canine pyruvate kinase deficiency, Exp Hematol., 22, 866 Blanco, 1997, Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients, Thromb. Haemost., 77, 656, 10.1055/s-0038-1656029